EP1907382B1 - Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt - Google Patents

Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt Download PDF

Info

Publication number
EP1907382B1
EP1907382B1 EP06769520.5A EP06769520A EP1907382B1 EP 1907382 B1 EP1907382 B1 EP 1907382B1 EP 06769520 A EP06769520 A EP 06769520A EP 1907382 B1 EP1907382 B1 EP 1907382B1
Authority
EP
European Patent Office
Prior art keywords
oxadiazol
oxy
trifluoromethyl
pyridin
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06769520.5A
Other languages
German (de)
English (en)
Other versions
EP1907382A1 (fr
Inventor
David Alexander Learmonth
Laszlo Erno Kiss
Pedro Nuno Leal Palma
Humberto Dos Santos Ferreira
Patrício Manuel Vieira Araújo Soares Da Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515327A external-priority patent/GB0515327D0/en
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Priority to SI200631969T priority Critical patent/SI1907382T1/sl
Priority to EP10012967A priority patent/EP2301934A1/fr
Priority to PL06769520T priority patent/PL1907382T3/pl
Priority to EP06769520.5A priority patent/EP1907382B1/fr
Publication of EP1907382A1 publication Critical patent/EP1907382A1/fr
Publication of EP1907382B1 publication Critical patent/EP1907382B1/fr
Application granted granted Critical
Priority to CY20151100748T priority patent/CY1116754T1/el
Priority to LU93327C priority patent/LU93327I2/fr
Priority to CY2016045C priority patent/CY2016045I1/el
Priority to NL300848C priority patent/NL300848I2/nl
Priority to HUS1600056C priority patent/HUS000502I2/hu
Priority to LTPA2016036C priority patent/LTC1907382I2/lt
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.
  • L-DOPA levodopa
  • CMT catechol-O-methyltransferase
  • AADC peripheral amino acid decarboxylase
  • L-DOPA induced clinical improvement is brief as a result of the short in vivo half-life of L-DOPA which contrasts with the long half-life of 3-OMD.
  • 3-OMD competes with L-DOPA for transport across the blood-brain barrier (BBB), which means that only a very limited amount of an orally administered dose of L-DOPA actually reaches the site of action, i.e. the brain.
  • BBB blood-brain barrier
  • L-DOPA induced clinical improvement declines at the end of each dose cycle, giving rise to the so-called 'wearing-off' pattern of motor fluctuations.
  • COMT inhibition protects L-DOPA from metabolic breakdown in the periphery through O-methylation, such that with repeated doses of L-DOPA, the mean plasma L-DOPA concentration is raised.
  • a significantly greater percentage of the orally administered dose of L-DOPA is able to reach the site of action.
  • COMT inhibition serves to increase the bioavailability of L-DOPA and the duration of antiparkinsonian action is prolonged with single doses of L-DOPA ( Nutt, J.G., Lancet, 351:1221-1222,1998 ).
  • tolcapone 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone (Tolcapone, Australian pat. AU-B-69764/87 ), (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (Entacapone, German pat. DE 3740383 A1 ) and BIA 3-202 (American pat. US 6512136 ) which all have inhibition constants in the low nanomolar range.
  • tolcapone differs from entacapone and BIA 3-202 in that it easily enters the central nervous systems (CNS) and is able to inhibit cerebral COMT as well as peripheral COMT.
  • CNS central nervous systems
  • central inhibition may be less important if the more significant action of inhibiting COMT is to prevent breakdown of L-DOPA in the periphery. Indeed, the use of COMT inhibitors which do not penetrate into the brain at clinically relevant doses may avoid potential undesired CNS side-effects of these agents.
  • tolcapone may be reduced metabolically to reactive intermediates and it has been speculated that these may form covalent adducts with hepatic proteins resulting in hepatocellular injury (Smith, K.S. et al, Chem. Res. Toxicol., 16:123-128,2003).
  • Entacapone on the other hand, although sharing the same nitrocatechol pharmacophore with tolcapone, is not associated with liver toxicity and is generally regarded as a safe drug. Unfortunately however, entacapone is a significantly less potent COMT inhibitor than tolcapone and has a much shorter in-vivo half-life. This means that entacapone has a very limited duration of effect and as a consequence, the drug must be administered in very high doses with every dose of L-DOPA taken by the patient. As such, the clinical efficacy of entacapone has been questioned - indeed a recent study ( Parashos, S.A. et al., Clin. Neuropharmacol., 27(3): 119-123, 2004 ) revealed that the principal reason for discontinuation of entacapone treatment in Parkinson's disease patients was a perceived lack of efficacy.
  • EP 1 167 342 A1 discloses carbonyl substituted 3,4-dihydroxy-5-nitrobenzoyl pharmacophore for COMT inhibitors.
  • the COMT inhibitor should be endowed with greater potency and duration of COMT inhibition than entacapone, which would lead to greater clinical efficacy.
  • the COMT inhibitor should, unlike tolcapone, have limited access to the CNS, i.e. it should preferentially inhibit peripheral COMT rather than central COMT.
  • the COMT inhibitor should combine the aforementioned features and in addition should not be endowed with potential to cause liver toxicity as seen with tolcapone.
  • This substance is a 3,5-disubstituted-[1,2,4]-oxadiazole with the methyl group occupying position C-3 of the heterocyclic oxadiazolyl ring and the nitrocatecholic pharmacophore attached to C-5.
  • regioisomeric 1,3,4-oxadiazoles wherein the nitrocatechol pharmacophore is attached to C-2 of the oxadiazolyl central ring are also usually less active in terms of COMT inhibition.
  • regioisomers 2 and 3 of the prior art oxadiazole 1 which we have also synthesised and evaluated in vivo;
  • the present invention relates to nitrocatecholic COMT inhibitors which are devoid of, or have greatly reduced, toxicity risk. Furthermore, it has been unexpectedly ascertained that it is the introduction of a nitrogen-based heterocyclic group in N-oxidised form, such as, for example, a pyridine N-oxide, that determines the lack of toxic effects of the nitrocatecholic compounds.
  • compounds of general formula I are COMT inhibitors which are endowed with balanced properties of bioactivity, bioavailability and, in particular, safety: wherein R 1 and R 2 are independently from each other hydrogen; Y represents an atom of oxygen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 represents a pyridine N-oxide group according to the formula A, B or C, which is connected as indicated by the unmarked bond: where R 4 , R 5 , R 6 and R 7 independently from each other represent hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -thioalkyl, C 1 -C 6 -alkoxy, C 6 -C 12 -aryloxy or a C 6 -C 12 -thioaryl group, C 1 -C 6 -alkanoyl or C 7 -C 13 -aroyl group, amino, C 1 -C 6 - alkylamino, C 1 -C 6 - al
  • the regioisomers of the central unit include both regioisomers realizable by exchange of the nitrocatechol moiety and the -(X) n -(Y) m -R 3 moiety.
  • C 1 -C 6 -alkyl residues represent methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl or hexyl.
  • C 1 -C 6 -thioalkyl residues represent thiomethyl, thioethyl, thio-n-propyl, thio-isopropyl, thio-n-butyl, thio-n-pentyl and thio-n-hexyl.
  • C 1 -C 6 -alkoxy residues represent methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy and tert-butoxy.
  • C 6 -C 12 -aryloxy residues represent phenoxy or naphthoxy which may optionally be substituted.
  • C 6 -C 12 -thioaryl residues represent thiophenyl and thionaphthyl which may optionally be substituted.
  • C 1 -C 6 -alkanoyl residues represent methanoyl, ethanoyl, propanoyl or butanoyl.
  • C 7 -C 13 -aroyl residues represent benzoyl and naphthoyl.
  • C 1 -C 6 -alkylamino residues represent methylamino, ethylamino, n-propylamino, isopropylamino and n-butylamino.
  • C 1 -C 6 -dialkylamino residues represent dimethylamino, diethylamino, di-n-propylamino, di-n-butylamino, di-isopropylamino, methylethylamino, methylpropylamino and ethylpropylamino.
  • C 3 -C 12 -cycloalkylamino residues represent pyrrolidino, piperidino, cyclohexylamino and dicyclohexylamino.
  • C 3 -C 12 -heterocycloalkylamino residues represent morpholino, 2,6-dimethylmorpholino, 3,5-dimethylmorpholino, piperazino, N-methylpiperazino and N-ethylpiperazino.
  • C 1 -C 6 -alkylsulphonyl or C 6 -C 12 -arylsulphonyl residues represent methylsufonyl, ethylsulfonyl, phenylsulfonyl, and tolylsulfonyl.
  • halogen residues represent chloro, bromo, iodo and fluoro.
  • C 1 -C 6 -haloalkyl represents chloromethyl, fluoromethyl, dichloromethyl, difluoromethyl, trichloromethyl and trifluoromethyl.
  • heteroaryl residues represent pyridyl, pyrimidyl, isoxazolyl, oxazolyl, isoxadiazolyl, oxadiazolyl, triazolyl and tetrazolyl.
  • residues R 4 , R 5 , R 6 and R 7 taken together represent aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings
  • preferred combined residues are indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, naphthyridinyl, isoquinolyl and quinolyl.
  • the central unit may be selected from a heteroaromatic five-membered ring which includes 1 to 4 of the heteroatoms N, O and S.
  • the central unit P may be selected from the regioisomers of 1,3,4-oxadiazol-2,5-diyl, 1,2,4-oxadiazol-3,5-diyl, 4-methyl-4H-1,2,4-triazol-3,5-diyl, 1,3,5-triazin-2,4-diyl, 1,2,4-triazin-3,5-diyl, 2H-tetrazol-2,5-diyl, 1,2,3-thiadiazol-4,5-diyl, 1-alkyl-3-(alkoxycarbonyl)-1 H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl and wherein alkoxy is represented by methoxy, ethoxy, n
  • Preferred compounds of the above general formula (I) having a 1,2,4-oxadiazol-3,5-diyl as central unit include 5-[3-(3,5-dichloro-1-oxy-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzene-1,2-diol, 5-[3-(2-chloro-1-oxy-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1 ,2-diol, 5-[3-(2-morpholin-4-yl-1-oxy-pyridine-4-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzene-1,2-diol, 3-nitro-5-[3-(1-oxy-4-trifluoromethyl-pyridin-3-yl)-1,2,4]oxadiazol-5-yl]-benzene-1,2-diol, 5-[3-(4-brom
  • Preferred compounds of the above general formula (I) having a 1,3,4-oxadiazol-2,5-diyl as central unit include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,3,4-oxadiazol-2-yl)-4,6-dimethylpyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,3,4-oxadiazol-2-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1,3,4-oxadia
  • Described are compounds of the above general formula (I) having a 4-methyl-4H-1,2,4-triazol-3,5-diyl as central unit include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-4-methyl-4H-1,2,4-triazol-3-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-4-methyl-4H-1,2,4-triazol-3-yl)-4,6-dimethylpyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-4-methyl-4H-1,2,4-triazol-3-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-4-methyl-4H-1,2,4-triazol-3-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(5-
  • Described are compounds of the above general formula (I) having a 1,3,5-triazin-2,4-diyl as central unit include 3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,3,5-triazin-2-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)-1,3,5-triazin-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)-1,3,5-triazin-2-yl)-2-methyl-4-(trifluoromethyl)pyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,3,5-triazin-2-y
  • Described are compounds of the above general formula (I) having a 1,2,4-triazin-3,5-diyl as a central unit include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-triazin-3-yl)-4-(trifluorormethyl)pyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-triazin-3-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-triazin-3-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-triazin-3-yl)-2-methyl-4-(trifluoromethyl)pyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-triazin-3
  • Described are compounds of the above general formula (I) having a (Z)-1-cyanoethen-1,2-diyl moiety as central unit include (Z)-3-(1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)vinyl)-4-(trifluorornethyl)pyridine 1-oxide, (Z)-2-chloro-3-(1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)vinyl)-4,6-dimethylpyridine 1-oxide, (Z)-3-(1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)vinyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, (Z)-5-(1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)vinyl)-2-(trifiuoromethyl)pyridine 1-oxide, (Z)-5-(1-cyano-2-(3,4-dihydroxy-5-nitropheny
  • Described are compounds of the above general formula (I) having as central unit a furan-2,4-diyl or a 3-alkoxycarbonylfuran-2,4-diyl moiety, wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, include 3-(4-(3,4-dihydroxy-5-nitrophenyl)-3-(ethoxycarbonyl)furan-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(4-(3,4-dihydroxy-5-nitrophenyl)-3-(ethoxycarbonyl)furan-2-yl)-4,6-dimethylpyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)-3-(ethoxycarbonyl)furan-2-yl)-2-methyl-6-(trifiuorornethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5
  • Described are compounds of the above general formula (I) having as central unit a 1H-imidazol-1,5-diyl moiety include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-imidazol-1-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-imidazol-1-yl)-4,6-dimethylpyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-imidazol-1-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-imidazol-1-yl)-2-(trifluoromethyl)pyridine 1-oxide, 3,5-dichloro-4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-imida
  • Described are compounds of the above general formula (I) having as central unit a isoxazol-3,5-diyl moiety include 3-(3-(3,4-dihydroxy-5-nitrophenyl)isoxazol-5-yl)-4-(trifiuorornethyl)pyridine 1-oxide, 2-chloro-3-(3-(3,4-dihydroxy-5-nitrophenyl)isoxazol-5-yl)-4,6-dimethylpyridine 1-oxide, 3-(3-(3,4-dihydroxy-5-nitrophenyl)isoxazol-5-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(3-(3,4-dihydroxy-5-nitrophenyl)isoxazol-5-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(3-(3,4-dihydroxy-5-nitrophenyl)isoxazol-5-yl)-2-(trifluoromethyl
  • Described are compounds of the above general formula (I) having as central unit a carbonyl moiety include 3-(3,4-dihydroxy-5-nitrobenzoyl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(3,4-dihydroxy-5-nitrobenzoyl)-4,6-dimethylpyridine 1-oxide, 3-(3,4-dihydroxy-5-nitrobenzoyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(3,4-dihydroxy-5-nitrobenzoyl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(3,4-dihydroxy-5-nitrobenzoyl)-2-methyl-4-(trifluoromethyl)pyridine 1-oxide, 3-(3,4-dihydroxy-5-nitrobenzoyl)-2,6-dimethyl-4-(trifluoromethyl)pyridine 1-oxide, 3,5-dichloro-4-(3,4-dihydroxy-5-nitrobenzoyl)pyridine 1-oxid
  • oxazol-2,4-diyl moiety examples include 3-(4-(3,4-dihydroxy-5-nitrophenyl)oxazol-2-yl)-4-(trifluoromethyl)pyridine 1 -oxide, 2-chloro-3-(4-(3,4-dihydroxy-5-nitrophenyl)oxazol-2-yl)-4,6-dimethylpyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)oxazol-2-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)oxazol-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)oxazol-2-yl)-2-methyl-4-(trifluoromethyl)pyridine 1-oxide,
  • benzene- 1,3-diyl moiety examples include 3-(3',4'-dihydroxy-5'-nitrobiphenyl-3-yl)-4- (trifluoromethyl)pyridine 1-oxide, 5-(3',4'-dihydroxy-5'-nitrobiphenyl-3-yl)-2-(trifluoromethyl)pyridine 1-oxide, 3,5-dichloro-4-(3',4'-dihydroxy-5'-nitrobiphenyl-3-yl)pyridine 1-oxide, 3-(3',4'-dihydroxy-5'-nitrobiphenyl-3-yl)-2-(trifluoromethyl)pyridine 1-oxide, and 3-(3',4'-dihydroxy-5'-nitrobiphenyl-3-yl)-5-(trifluoromethyl)pyridine 1-oxide.
  • Described are compounds of the above general formula (I) having as central unit an 1-H-pyrazol-1,5-diyl moiety include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1 H-pyrazol-1-yl)-4-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1 H-pyrazol-1-yl)-2-(trifluoromethyl)pyridine 1-oxide, 3,5-dichloro-4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)pyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1 H-pyrazol-1-yl)-2-(trifluoromethyl)pyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)-5-(trifluoromethyl)pyridine 1-oxide, and
  • pyrimidin-2,4-diyl moiety examples include 3-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-yl)-4,6-dimethylpyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-yl)-2-methyl-4-(trifluoromethyl)pyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)pyrimidin-2-y
  • Described are compounds of the above general formula (I) having as central unit an 1 H-pyrrol-2,5-diyl moiety include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1-methyl-3-(ethoxycarbonyl)-1 H-pyrrol-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-3-(ethoxycarbonyl)-1-methyl-1H-pyrrol-2-yl)-4,6-dimethylpyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1-methyl-1 H-pyrrol-2-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-1-ethyl-3-(ethoxycarbonyl)-1 H-pyrrol-2-yl)-2-(trifluoromethyl)pyridine 1-
  • Described are compounds of the above general formula (I) having as central unit an 2H-tetrazol-2,5-diyl moiety include 3-(5-(3,4-dihydroxy-5-nitrophenyl)-2H-tetrazol-2-yl)-4-(trifluoromethyl)pyridine 1-oxide, 5-(5-(3,4-dihydroxy-5-nitrophenyl)-2H-tetrazol-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 3,5-dichloro-4-(5-(3,4-dihydroxy-5-nitrophenyl)-2H-tetrazol-2-yl)pyridine 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-2H-tetrazol-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, and 3-(5-(3,4-dihydroxy-5-nitrophenyl)-2H-tetrazol-2-yl)-5-(trifluoromethyl)
  • Described are compounds of the above general formula (I) having as central unit an 1,2,3-thiadiazol-4,5-diyl moiety include 3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,2,3-thiadiazol-5-yl)-4-(trifiuoromethyl)pyridine 1-oxide, 2-chloro-3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,2,3-thiadiazol-5-yl)-4,6-dimethylpyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)-1,2,3-thiadiazol-5-yl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)-1,2,3-thiadiazol-5-yl)-2-(trifiuoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)-1,2,3-thiadia
  • thiazol-2,4-diyl moiety examples include 3-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2-yl)-4-trifluoromethyl)pyridine 1-oxide, 2-chloro-3-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2- yl)-4,6-dimethylpyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2-yl)-2-methyl-6-(trifluoromethyl)pyridine-1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2-yl)-2-(trifluoromethyl)pyridine 1-oxide, 5-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2-yl)- 2-methyl-4-(trifluoromethyl)pyridine 1-oxide, 3-(4-(3,4-dihydroxy-5-nitrophenyl)thiazol-2-
  • compounds of the general formula I wherein the central unit consists of a 1,2,4-oxadiazo-3,5-diyl-moiety can be prepared by a process wherein a compound of the general formula IIA, IIB or IIC, wherein R 4 , R 5 , R 6 and R 7 are defined as in the general formula I, is subjected to a cyclisation reaction comprising condensation and dehydration with a compound of the general formula III, wherein R 8 and R 9 independently from each other represent hydrogen or suitable protective groups for aromatic hydroxyl groups, under conditions suitable to produce oxadiazole derivatives of formula IVA, IVB or IVC, followed by removal of the hydroxyl protecting groups to provide the compounds of general formula I wherein the central unit consists of a 1,2,4-oxadiazo-3,5-diyl-moiety.
  • the compounds of the general formula I wherein the central unit consists of a 1,2,4-oxadiazo-3,5-diyl-moiety can be prepared by a process wherein a compound of the general formula VA, VB or VC, wherein R 4 , R 5 , R 6 and R 7 are defined as in the general formula I, is subjected to a cyclisation reaction comprising condensation and dehydration with a compound of the general formula III under conditions suitable to produce oxadiazole derivatives of formula VIA, VIB or VIC, followed by oxidation of the pyridyl nitrogen atom to give a compound according to formula IVA, IVB or IVC as shown above and finally, if necessary, the removal of the hydroxyl protecting groups to provide the compounds of general formula I wherein the central unit consists of a 1,2,4-oxadiazo-3,5-diyl-moiety.
  • Suitable protective groups for aromatic hydroxyl groups are well known in the art.
  • suitable protective groups for aromatic hydroxyl groups include methyl, ethyl, isopropyl, benzyl, 4-methoxybenzyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, tetrahydropyranyl, phenacyl, allyl, trimethylsilyl, tert-butyldimethylsilyl, benzyloxycarbonyl, tert-butoxycarbonyl, ester, sulphonate, carbamate, phosphinate, acetal and ketal derivatives.
  • one of the groups R 8 and R 9 is hydrogen and the other is methyl. In another instance, R 8 represents methyl and R 9 represents hydrogen.
  • the protective groups R 8 and R 9 may be replaced with hydrogen or a group which is hydrolysable under physiological conditions.
  • the protective groups R 8 and R 9 may be removed independently from each other in separate reaction steps or they may be removed in the same reaction step. Likewise, the insertion of a group which is hydrolysable under physiological conditions may take place either in the same or in a subsequent reaction step.
  • conditions suitable to produce oxadiazole derivatives comprise conditions which give the oxadiazole derivative in high yield and purity.
  • the yield of the desired oxadiazole derivative is at least 70%, more preferably 75 to 99%, even more preferably 80 to 97%, and most preferably 85 to 95%.
  • the purity of the desired oxadiazole derivative is at least 90%, more preferably at least 95%, even more preferably at least 99%, and most preferably at least 99.5%.
  • the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the oxadiazole. Parameters to be taken into consideration by the skilled person include, but are not limited to, reagents effecting the condensation and dehydration agents, choice of protective groups R 8 and R 9 , solvent system, reaction temperature and reaction time and solubility of reagents.
  • the compound of general formula III requires activation before condensation with a compound of formula IIA-IIC or VA-VC.
  • Suitable reagents for activation of the compound of formula III include 1,1-carbonyldiimidazole, thionyl chloride, sulfonylchloride, N,N'-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide, phosgene, PCl 3 , POCl 3 , PCl 5 , anhydrides, trichlorotriazine and chlorodimethoxytriazine and the like.
  • 1,1-carbonyldiimidazole and thionyl chloride are particularly preferable.
  • the same reagents can be employed to effect the cyclisation step, which consists of condensation and dehydration.
  • Alternative reagents to effect condensation and/or dehydration include pyridine and tetrabutylammonium fluoride.
  • the dehydration can be effected by thermal heating of the reaction mixture in conjunction with the aforementioned reagents.
  • the compound of general formula III can be activated with an excess of a reagent such as thionyl chloride in a suitable solvent or without the need for additional solvent. If preferred, the excess reagent can then be removed, e.g. by distillation, and replaced with a solvent and another reagent such as pyridine to effect the condensation and dehydration steps.
  • a reagent such as thionyl chloride in a suitable solvent or without the need for additional solvent.
  • the excess reagent can then be removed, e.g. by distillation, and replaced with a solvent and another reagent such as pyridine to effect the condensation and dehydration steps.
  • Preferred solvent systems for activating the compound of general formula III, and cyclisation with compounds of general formulas IIA-IIC or VA-VC are dipolar aprotic solvents including dimethylformamide, dimethylsulfoxide, dimethylacetamide and N-methylpyrrolidinone. Particularly preferable are dimethylsulfoxide and dimethylacetamide
  • reaction temperatures and reaction times depend on the reactivity of the utilized reagents for effecting condensation and dehydration.
  • the reaction temperature is in the range of 0°C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 150°C, and most preferably in the range of 25 to 120°C
  • the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 6 hours.
  • the condensation and dehydration reaction is carried out in the presence of an organic or inorganic base.
  • Suitable preferred bases include triethylamine, tributylamine, 2,6-lutidine, N-methylmorpholine, pyridine, imidazole, N-methylimidazole and 4-dimethylaminopyridine.
  • Particularly preferred bases include pyridine, N-methylimidazole and 4-dimethylaminopyridine.
  • condensation and dehydration are conducted in two separate reaction steps.
  • different condensation and dehydration agents and solvent systems may be utilized to optimize yield and purity of the obtained product.
  • condensation and dehydration are conducted sequentially in the same vessel without isolation of the O-acylated intermediates.
  • the reagents effecting the condensation and dehydration can be the same or different but are preferably identical.
  • the amount of reagents effecting the condensation and dehydration are not critical. Typical amounts of reagents effecting the condensation and dehydration include at least an amount of 1 mol, preferably 2.1 mol to 5 mol, more preferably 2.2 to 4 mol, and most preferably 2.3 mol to 3 mol, per mol pyridine derivative. In cases in which the reagents effecting the condensation and dehydration also serves as solvent or co-solvent, the excess amount may be much higher.
  • the invention may include a step in which the nitrogen atom of the pyridyl moiety VIA, VIB or VIC is oxidized under suitable conditions to the corresponding pyridyl-N-oxide derivative IVA, IVB or IVC after the cyclisation reaction.
  • suitable oxidative conditions to produce the pyridyl-N-oxide comprise conditions which give the pyridyl-N-oxide derivative in high yield and purity
  • the yield of the desired pyridyl-N-oxide derivative is at least 90%, more preferably 92 to 99%, even more preferably 94 to 98%, and most preferably 95 to 97%.
  • the purity of the desired pyridyl-N-oxide derivative is at least 90%, more preferably at least 95%, even more preferably at least 99%, and most preferably at least 99.5%.
  • the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the pyridyl-N-oxide. Parameters to be taken into consideration by the skilled person include, but are not limited to, oxidizing agent, amount of oxidizing agent, choice of protective groups, solvent system, reaction temperature and reaction time and solubility of reagents.
  • Preferred oxidizing agents include hydrogen peroxide, MnO 2 , peracetic acid, trifluoroperacetic acid, t-butylhydroperoxide, m-chloroperoxybenzoic acid, persulfuric acids, Oxone®, urea hydrogen peroxide complex and trifluoroacetic anhydride, pyridinium chlorochromate and permanganate ions. Particularly preferred is urea hydrogen peroxide complex and trifluoroacetic anhydride.
  • the preferred amount of oxidizing agent is in the range of equimolar amounts to a 20-fold excess to the pyridine derivative.
  • amount of oxidizing agent is in the range of a 1.2- fold to 10-fold excess, more preferably 1.5-fold to 8-fold excess and most preferably 2-fold to 5-fold excess.
  • Preferred solvent systems for conducting the oxidation are solvents which are inert to the oxidizing agent.
  • Particularly preferred are halogenated solvents, such as dichloromethane, chloroform, chlorobenzene and carbon tetrachloride, aromatic solvents such as benzene and toluene, alkanes such as cyclohexane and hexane, and ethers such as THF, 1,4-dioxane and tert-butylmethylether.
  • reaction temperatures and reaction times depend on the reactivity of the utilized oxidizing agent.
  • the reaction temperature is in the range of 0°C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 100°C, and most preferably in the range of 40 to 80 °C.
  • the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 6 hours.
  • the oxidation of the pyridyl nitrogen atom can be carried out at any stage of the process of preparation of compounds according to the general formula I.
  • the oxidation is conducted before formation of the compounds of formulae IIA-IIC, or alternatively after formation of the oxadiazole ring as in compounds of formulae VIA-VIC.
  • compounds of formula IIA, IIB or IIC are prepared by reacting compounds of the general formula VIIA, VIIB or VIIC, with hydroxylamine in the presence of a chelating agent under suitable reaction conditions.
  • compounds of formula VA, VB or VC are prepared by reacting compounds of the general formula VIIIA, VIIIB or VIIIC, with hydroxylamine in the presence of a chelating agent under suitable reaction conditions.
  • suitable reaction conditions of the above reactions comprise conditions which give the amidoxime derivative in high yield and purity.
  • the yield of the desired amidoxime derivative is at least 70%, more preferably 72 to 95%, even more preferably 75 to 90%, and most preferably 78 to 85%.
  • the purity of the desired amidoxime derivative is at least 90%, more preferably at least 95%, even more preferably at least 96%, and most preferably at least 97%.
  • the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the amidoxime. Parameters to be taken into consideration by the skilled person include, but are not limited to, amount of hydroxylamine, choice of catalyst, nature of substituents R 4 to R 7 , solvent system, reaction temperature and reaction time and solubility of reagents.
  • the preferred amount of hydroxylamine is in the range of equimolar amounts to a 50-fold excess to the pyridine derivative.
  • the amount of hydroxylamine is in the range of a 1.2- fold to 20-fold excess, more preferably 1.5-fold to 10-fold excess and most preferably 3-fold to 5-fold excess.
  • Preferred chelating agents include 8-hydroxyquinoline, ortho-phenanthroline and hydrates and derivatives thereof.
  • the preferred amount of chelating agent is in the range 0.1-10 mol%, more preferably 0.5-5 mol%, more preferably 0.75-3 mol% and most preferably 1- 1.5 mol%.
  • the solvent system is not particularly limited and includes water, alcohols such as methanol, ethanol or isopropanol, ethers such as THF or 1,4-dioxane, and dipolar aprotic solvents, such as dimethylsulfoxide and the like or mixtures of these solvents.
  • the reaction temperature is in the range of 0°C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 100°C and most preferably in the range of 40 to 80°C.
  • the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 8 hours.
  • inert pharmaceutically acceptable carriers are admixed with the active compounds.
  • the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules and capsules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it may also be an encapsulating material.
  • the pharmaceutical preparation is in unit dosage form, e.g. packaged preparation, the package containing discrete quantities of preparation such as packeted tablets, capsules and powders in vials or ampoules.
  • the dosages may be varied depending on the requirement of the patient, the severity of the disease and the particular compound being employed. For convenience, the total daily dosage may be divided and administered in portions throughout the day. Determination of the proper dosage for a particular situation is within the skill of those in the medical art.
  • COMT activity was evaluated by the ability to methylate adrenaline to metanephrine, as previously described ( Vieira-Coelho, M.A., Soares-da-Silva, P., Brain Res, 1999, 821, 69-78 ).
  • Aliquots of 0.5 ml of liver homogenates were preincubated for 20 min with 0.4 ml of phosphate buffer (5 mM); thereafter, the reaction mixture was incubated for 10 min with adrenaline (500 ⁇ M; 0.1 ml) in the presence of a saturating concentration of S-adenosyl-L-methionine, the methyl donor (250 ⁇ M).
  • the incubation medium also contained pargyline (100 ⁇ M), MgCl 2 (100 ⁇ M) and EGTA (1 mM).
  • the preincubation and incubation were carried out at 37 °C under conditions of light protection with continuous shaking and without oxygenation.
  • the tubes were transferred to ice and the reaction was stopped by the addition of 200 ⁇ l of 2 M perchloric acid.
  • the samples were then centrifuged (200 x g, 4 min, 4 °C), and 500 ⁇ l aliquots of the supernatant, filtered on 0.22 ⁇ m pore size
  • Spin-X filter tubes (Costar) were used for the assay of metanephrine by high pressure liquid chromatography with electrochemical detection.
  • test compounds in 0.5% carboxymethylcellulose were given by gastric tube to overnight fasted mice. Thereafter, at defined intervals, livers were removed and used to determine COMT activity as described above. Where applicable, blank solutions containing 0.5% carboxymethylcellulose were used as control.
  • Rats fasted overnight were administered orally with tolcapone, entacapone and compounds of general formula I (all at 3 mg/kg) or vehicle (0.5% carboxymethylcellulose, 4 ml/kg).
  • rats were administered orally with L-DOPA (12 mg/kg) plus benserazide (3 mg/kg) or with vehicle (0.5% carboxymethylcellulose, 4 ml/kg).
  • rats were anaesthetised with sodium pentobarbitone (60 mg/kg, i.p.), blood was collected through the vena cava and the whole brain was quickly removed.
  • the mobile phase was a degassed solution of citric acid 0.1 mM; sodium octylsulphate 0.5 mM; sodium acetate 0.1 M; Na 2 EDTA 0.17 mM; dibutylamine 1 mM and methanol (10% v/v), adjusted to pH 3.5 with PCA 2 M and pumped at a rate of 1.0 ml min -1 .
  • the detection was carried out electrochemically with a glassy carbon electrode, an Ag/AgCl reference electrode and an amperometric detector (Gilson 142); the detector cell was operated at 0.75 V. The current produced was monitored using the Gilson Unipoint HPLC software.
  • the method which detects cell toxicity of a test substance, follows that described by Pedrosa and Soares-da-Silva (Br. J. Pharmacol., 137, 1 1305-1313, 2002 ). Briefly, Neuro 2A mouse neuroblastoma cells were seeded in 96-well plates in 200 ⁇ L per well of culture medium for cell attachment (CMA), under a CO 2 /air (5%/95%) humidified atmosphere at 37 °C. Controls of the test system prior to incubations consisted in a morphological control (light microscopy) of the cultured cells: attachment, spreading and density. Five days after seeding (24 h after cells become confluent), the test compounds were incubated for 24 h with cultured cells. Cultures with no test article or ethanol were run in parallel as negative and positive controls. All incubations contained the same percentage of solvent needed for the test compound.
  • calcein-AM Molecular Probes, Eugene, OR, USA.
  • the membrane permeant calcein-AM a nonfluorescent dye, is taken up and converted by intracellular esterases to membrane impermeant calcein, which emits green fluorescence.
  • Hanks' medium medium composition, in mM: NaCl, 137; KCl, 5; MgSO 4 , 0.8; Na 2 HPO 4 , 0.33; KH 2 PO 4 , 0.44; CaCl 2 , 0.25; MgCl 2 , 1.0; Tris HCl, 0.15 and sodium butyrate, 1.0, pH
  • Table 1 shows the effects of standard COMT inhibitors, tolcapone and entacapone, and compounds of general formula I upon mouse liver COMT activity 3 h after their oral administration (3 mg/kg). Also shown in table 1 is the cell viability after 24 h expsoure to tolcapone, entacapone and compounds of general formula I (all at 30 ⁇ M) in Neuro 2A cells. Table 1. Mouse Liver COMT activity (% control) after 3 mg/kg (oral) administration of compounds listed and Neuro 2A cell viability (% of viable cells) No.
  • Table 3 shows percentage changes in plasma levels of L-DOPA and 3-O-methyl-L-DOPA (3-OMD) of rats treated with L-DOPA plus benserazide at 2 h after the administration of entacapone, tolcapone and compounds of general formula I (3 mg/kg).
  • L-DOPA plus benserazide were administered 1 h before collection of plasma samples. This time-point was chosen because it represented the t max for L-DOPA.
  • compounds of general formula I produced significant increases in plasma L-DOPA accompanied by marked decrease in plasma 3-O-methyl-L-DOPA. Table 3.
  • Compounds of general formula I are very potent catechol-O-methyltransferase (COMT) inhibitors with significantly reduced toxicity.
  • Compounds of general formula I have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders where inhibition of O-methylation of catecholamines may be of therapeutical benefit, such as mood disorders, Parkinson's disease and parkinsonian disorders, restless legs syndrome, gastrointestinal disturbances, edema formation states and hypertension.
  • the possibility to use a potent, long-acting inhibitor with improved safety profile opens new perspectives in the treatment of Parkinson's disease and parkinsonian disorders, gastrointestinal disturbances, edema formation states, and hypertension by improving the safety of nitrocatecholic COMT inhibitors whilst improving or maintaining duration and selectivity of COMT inhibition. This is particularly important when thinking of treating patients afflicted by Parkinson's disease who are taking L-DOPA plus a peripheral AADC inhibitor due to the fact that this is long-term treatment.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)

Claims (24)

  1. Composé de formule (I) :
    Figure imgb0062
     dans laquelle R1 et R2 sont indépendamment l'un de l'autre de l'hydrogène ; X représente un groupement méthylène ; Y représente un atome d'oxygène ou de soufre ; n représente le nombre 0, 1, 2 ou 3 et m représente le nombre 0 ou 1 ; R3 représente un groupement N-oxyde de pyridine selon la formule A, B ou C, qui est raccordé comme indiqué par la liaison non marquée :
    Figure imgb0063
     dans laquelle R4, R5, R6 et R7 représentent indépendamment l'un de l'autre de l'hydrogène, un groupement alkyle en C1-C6, thioalkyle en C1-C6, alcoxy en C1-C6, aryloxy en C6-C12 ou thioaryle en C6-C12, alcanoyle en C1-C6 ou aroyle en C7-C13, amino, alkylamino en C1-C6, dialkylamino en C1-C6, cycloalkylamino en C3-C12 ou hétérocycloalkylamino en C3-C12, alkylsulfonyle en C1-C6, ou arylsulfonyle en C6-C12, un halogène, un groupement haloalkyle en C1-C6, trifluorométhyle, cyano, nitro ou hétéroaryle ; ou dans laquelle deux résidus R4, R5, R6 et R7 ou plus pris conjointement représentent des noyaux aliphatiques ou hétéroaliphatiques ou des noyaux aromatiques ou hétéroaromatiques et dans laquelle P représente une unité centrale choisie parmi des régioisomères de 1,2,4-oxadiazol-3,5-diyle et 1,3,4-oxadiazol-2,5-diyle et dans laquelle les régioisomères de l'unité centrale comprennent à la fois des régioisomères réalisables par échange du fragment nitrocatéchol et du fragment -(X)n-(Y)m-R3.
  2. Composé selon la revendication 1 de formule IVA, IVB ou IVC,
    Figure imgb0064
     dans laquelle R4, R5, R6 et R7 sont définis comme dans la revendication 1, où R8 et R9 représentent de l'hydrogène, ou un de ses sels acceptable au plan pharmaceutique.
  3. Composé selon la revendication 1, choisi parmi les suivants : 5-[3-(3,5-dichloro-1-oxy-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-chloro-1-oxy-pyridin-4-yl)oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-morpholin-4-yl-1-oxy-pyridine-4-yl)-oxadiazol-5-yl]-3-nitrobenzène-1,2-diol,3-nitro-5-[3-(1-oxy-4-trifluoro-méthyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-benzène-1,2-diol, 5-[3-(4-bromo-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-chloro-6-méthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-morpholin-4-yl-1-oxy-pyridin-3-yl)-[1,2,4]-oxadiazol-5-yl]nitro-benzène-1,2-diol, 3-nitro-5-[3-(1-oxy-6-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]benzène-1,2-diol, 5-[3-(2-méthyl-1-oxy-6-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(6-méthyl-1-oxy-4-trifluorométhyl-pyridin-3-yl)oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2,6-diméthyl-1-oxy-4-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-méthyl-1-oxy-6-phényl-4-trifluoro-méthyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(6-méthyl-1-oxy-2-phényl-4-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-bromo-6-méthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-chloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]-oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-bromo-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol, 5-[3-(2-bromo-4,5,6-triméthyl-1-oxy-pyridin-3-yl)-[1,2,4]-oxadiazol-5-yl]-3-nitrobenzène-1,2-diol, 5-[3-(2-chloro-4,5,6-triméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol, 5-[3-(2,5-dichloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-diol, 5-[3-(2-bromo-5-chloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol et 3-nitro-5-[3-(1-oxy-2-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]benzène-1,2-diol.
  4. Composé selon la revendication 1, qui est le 3-nitro-5-[3-(1-oxy-4-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]benzène-1,2-diol.
  5. Composé selon la revendication 1, qui est le 5-[3-(2-méthyl-1-oxy-6-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol.
  6. Composé selon la revendication 1, qui est le 5-[3-(6-méthyl-1-oxy-4-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzène-1,2-diol.
  7. Composé selon la revendication 1, qui est le 5-[3-(2-chloro-4,5,6-triméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol.
  8. Composé selon la revendication 1, qui est le 3-nitro-5-[3-(1-oxy-2-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]benzène-1,2-diol.
  9. Composé selon la revendication 1, qui est le 3-nitro-5-[3-(1-oxy-6-trifluorométhyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]benzène-1,2-diol.
  10. Composé selon la revendication 1, qui est le 5-[3-(2,5-dichloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol.
  11. Composé selon la revendication 1, qui est le 5-[3-(2-bromo-5-chloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol.
  12. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 11 en combinaison avec un véhicule acceptable au plan pharmaceutique.
  13. Composition pharmaceutique selon la revendication 12, dans laquelle le véhicule acceptable au plan pharmaceutique est solide, la préparation solide se présentant sous la forme d'une poudre et/ou de comprimés et/ou de granulés dispersables et/ou de capsules.
  14. Composé selon l'une quelconque des revendications 1 à 11 pour usage en thérapie.
  15. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement d'un sujet atteint de troubles du système nerveux central ou périphérique.
  16. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement des troubles de l'humeur, de la maladie de Parkinson et des troubles parkinsoniens, du syndrome d'impatience musculaire, des troubles gastro-intestinaux, des états de formation d'oedèmes ou de l'hypertension.
  17. Composé selon l'une quelconque des revendications 1 à 11 pour usage comme inhibiteur de COMT.
  18. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement de la maladie de Parkinson.
  19. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement de troubles parkinsoniens.
  20. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement du syndrome d'impatience musculaire.
  21. Composé selon l'une quelconque des revendications 1 à 11 ou composition selon la revendication 12 ou la revendication 13 pour usage dans le traitement d'états de formation d'oedèmes ou de l'hypertension.
  22. Composé ou composition pour usage selon la revendication 18 ou la revendication 19 chez un patient subissant un traitement avec de la L-DOPA et un inhibiteur d'AADC périphérique.
  23. Composé selon la revendication 1, dans lequel le composé est le 5-[3-(2,5-dichloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzène-1,2-diol pour utilisation dans le traitement de la maladie de Parkinson chez un patient subissant un traitement avec de la L-DOPA et un inhibiteur d'AADC périphérique.
  24. Composition pharmaceutique selon la revendication 12, dans laquelle le composé est le 5-[3-(2,5-dichloro-4,6-diméthyl-1-oxy-pyridin-3-yl)-[1,2,4]-oxadiazol-5-yl]-3-nitrobenzène-1,2-diol pour usage dans le traitement de la maladie de Parkinson chez un patient subissant un traitement avec de la L-DOPA et un inhibiteur d'AADC périphérique.
EP06769520.5A 2005-07-26 2006-07-26 Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt Active EP1907382B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SI200631969T SI1907382T1 (sl) 2005-07-26 2006-07-26 Nitrokateholni derivati kot inhibitorji COMT
EP10012967A EP2301934A1 (fr) 2005-07-26 2006-07-26 Dérivés du nitrocatechol en tant qu'inhibiteurs COMT
PL06769520T PL1907382T3 (pl) 2005-07-26 2006-07-26 Pochodne nitrokatecholowe jako inhibitory COMT
EP06769520.5A EP1907382B1 (fr) 2005-07-26 2006-07-26 Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt
CY20151100748T CY1116754T1 (el) 2005-07-26 2015-08-26 Παραγωγα νιτροκατεχολης ως αναστολεις της comt
LU93327C LU93327I2 (fr) 2005-07-26 2016-11-30 Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
CY2016045C CY2016045I1 (el) 2005-07-26 2016-12-09 Παραγωγα νιτροκατεχολης ως αναστολεις της comt
NL300848C NL300848I2 (fr) 2005-07-26 2016-12-12
HUS1600056C HUS000502I2 (hu) 2005-07-26 2016-12-13 Opikapon vagy egy gyógyászatilag elfogadható sója
LTPA2016036C LTC1907382I2 (lt) 2005-07-26 2016-12-13 Nitrokatechnolio dariniai, kaip COMT inhibitoriai

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0515327A GB0515327D0 (en) 2005-07-26 2005-07-26 Comt inhibitors
EP06008203 2006-04-20
EP06011073 2006-05-30
EP06769520.5A EP1907382B1 (fr) 2005-07-26 2006-07-26 Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt
PCT/PT2006/000020 WO2007013830A1 (fr) 2005-07-26 2006-07-26 Derives de nitrocatechol utilises en tant qu'inhibiteurs comt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10012967A Division-Into EP2301934A1 (fr) 2005-07-26 2006-07-26 Dérivés du nitrocatechol en tant qu'inhibiteurs COMT

Publications (2)

Publication Number Publication Date
EP1907382A1 EP1907382A1 (fr) 2008-04-09
EP1907382B1 true EP1907382B1 (fr) 2015-05-27

Family

ID=37056522

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06769520.5A Active EP1907382B1 (fr) 2005-07-26 2006-07-26 Dérivés de nitrocatechol utilisés en tant qu'inhibiteurs comt
EP10012967A Withdrawn EP2301934A1 (fr) 2005-07-26 2006-07-26 Dérivés du nitrocatechol en tant qu'inhibiteurs COMT

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10012967A Withdrawn EP2301934A1 (fr) 2005-07-26 2006-07-26 Dérivés du nitrocatechol en tant qu'inhibiteurs COMT

Country Status (24)

Country Link
US (6) US8168793B2 (fr)
EP (2) EP1907382B1 (fr)
JP (3) JP5517453B2 (fr)
KR (1) KR101370280B1 (fr)
CN (1) CN102816157B (fr)
AR (1) AR058439A1 (fr)
AU (1) AU2006272978B2 (fr)
BR (1) BRPI0613859B8 (fr)
CA (1) CA2616377C (fr)
CY (2) CY1116754T1 (fr)
DK (1) DK1907382T3 (fr)
ES (1) ES2545178T3 (fr)
HK (1) HK1120266A1 (fr)
HU (2) HUE025466T2 (fr)
IL (1) IL188913A (fr)
LT (1) LTC1907382I2 (fr)
LU (1) LU93327I2 (fr)
NL (1) NL300848I2 (fr)
NO (2) NO341886B1 (fr)
NZ (1) NZ565460A (fr)
PL (1) PL1907382T3 (fr)
PT (1) PT1907382E (fr)
SI (1) SI1907382T1 (fr)
WO (1) WO2007013830A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (fr) 2006-04-10 2007-10-17 Portela & Ca., S.A. Derives de oxadiazole en tant qu' inhibiteurs de l'enzyme COMT
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
US8524746B2 (en) * 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
CN101965334A (zh) * 2007-10-24 2011-02-02 比艾尔-坡特拉有限公司 新的前体
RU2459812C2 (ru) 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции
AR070907A1 (es) 2008-03-17 2010-05-12 Bial Portela & Ca Sa Formas cristalinas de derivado de nitrocatecol
MX2011001046A (es) * 2008-07-29 2011-03-29 Bial Portela & Ca Sa Regimen de administracion para nitrocatecoles.
ES2730678T3 (es) * 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
ES2915698T3 (es) * 2009-04-01 2022-06-24 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
JP5529639B2 (ja) * 2009-06-18 2014-06-25 キッセイ薬品工業株式会社 新規なカテコール−ｏ−メチルトランスフェラーゼ阻害剤
JP5707063B2 (ja) * 2009-06-18 2015-04-22 キッセイ薬品工業株式会社 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
JP5433505B2 (ja) * 2009-06-18 2014-03-05 キッセイ薬品工業株式会社 ニトロカテコール誘導体の製造方法およびその製造中間体
KR20120092175A (ko) * 2009-12-04 2012-08-20 죤 이. 그랜트 카테콜-0-메틸-트랜스퍼라제 저해제를 사용한 충동 제어 장애의 치료
AU2011222856B2 (en) 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP2013053559A (ja) * 2011-09-05 2013-03-21 Suzuki Motor Corp 車両の衝突被害軽減制御装置
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
MX352996B (es) * 2012-06-30 2017-12-15 Dow Agrosciences Llc Procesos para la produccion de n-oxidos de piridina de sulfoximina n-sustituida.
CN105992648B (zh) * 2013-05-31 2019-04-26 彼克斯赛尔医疗科技有限公司 用于制备含有用于分析的细胞的样品流体的盒
KR20160067841A (ko) 2013-08-28 2016-06-14 메디베이션 테크놀로지즈, 인크. 헤테로사이클릭 화합물 및 사용 방법
WO2016083863A1 (fr) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Médicaments destinés au ralentissement de la progresssion de la maladie de parkinson
EP3265088A1 (fr) 2015-03-04 2018-01-10 Medivation Technologies LLC Bloqueurs des srebp destinés à l'utilisation dans le traitement de la fibrose hépatique, le cholestérol élevé et la résistance à l'insuline
CA2977539A1 (fr) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Inhibiteurs des proteines de liaison a l'element de regulation des sterols (srebp)
CN107922316B (zh) * 2015-06-23 2022-04-08 北京生命科学研究所 Fto抑制剂
JP2020158391A (ja) * 2017-06-13 2020-10-01 株式会社富士薬品 新規ニトロカテコール誘導体
GB2563858A (en) * 2017-06-27 2019-01-02 Azad Pharmaceutical Ingredients Ag New route of synthesis for opicapone
MX2020006283A (es) * 2017-12-18 2020-12-09 Unichem Lab Ltd Proceso para la preparación de opicapona y sus intermediarios.
EP3860603A1 (fr) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Procédés d'administration d'inhibiteurs de comt
CA3112994A1 (fr) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Procedes d'administration d'inhibiteurs de comt
CN115335036A (zh) 2020-03-13 2022-11-11 巴尔-波特拉及康邦亚股份有限公司 微粉化的奥匹卡朋
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
GB202219669D0 (en) 2022-12-23 2023-02-08 Bial Portela & Ca Sa Processes and intermediates for synthesising opicapone

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4264573A (en) 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
EP0072654A3 (fr) 1981-08-19 1983-08-24 Ecomax (U.K.) Limited Buse de distribution pour l'utilisation avec appareil de manutention de fibres minérales
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
EP0462639A1 (fr) 1990-06-05 1991-12-27 Shell Internationale Researchmaatschappij B.V. Préparation de dérivés de 2-chloropyridine
DK0487774T3 (da) 1990-11-29 1994-11-21 Wei Ming Pharmaceutical Mfg Co Hjælpestof til direkte tablettering
CA2126976A1 (fr) 1991-12-31 1993-07-08 Hisashi Takasugi Derives d'oxadiazole inhibiteurs de l'activite de l'acetylcholinesterase et agonistes muscariniques
JP3775684B2 (ja) * 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
IL131037A (en) 1999-07-22 2004-06-20 Israel Atomic Energy Comm Method for making threedimensional photonic band-gap crystals
NZ517221A (en) 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB0015228D0 (en) * 2000-06-21 2000-08-16 Portela & Ca Sa Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
GB2363792A (en) * 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
US6966488B2 (en) 2000-08-24 2005-11-22 Sagawa Express Co., Ltd. Card payment method for service charge concerning to physical distribution or transportation
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
WO2002051442A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
US20030187007A1 (en) 2001-05-30 2003-10-02 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
CA2449544A1 (fr) 2001-06-08 2002-12-19 Cytovia, Inc. 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations
US7115623B2 (en) * 2001-06-12 2006-10-03 Aska Pharmaceuticals Co., Ltd. PDE IV inhibitors
CN1292749C (zh) 2001-07-26 2007-01-03 默克专利股份有限公司 2－[5－(4－氟苯基)－3－吡啶基甲氨基甲基]苯并二氢吡喃及其生理学上可接受的盐的新用途
JP4379853B2 (ja) 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
CN100364531C (zh) 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
EP1578412B1 (fr) 2002-12-23 2010-09-29 Merck Frosst Company Compositions pharmaceutiques et méthode de traitement de la maladie de parkinson
WO2005006945A2 (fr) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Procedes de traitement de troubles neurologiques et composes utiles a cet effet
EP1663211B1 (fr) 2003-08-06 2010-01-20 Vertex Pharmaceuticals Incorporated Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ATE464303T1 (de) 2004-04-28 2010-04-15 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
DE202004011766U1 (de) 2004-07-28 2004-10-14 Enderle, Stefan Roboterbausatz für einen autonomen mobilen Roboter und mit Hilfe dieses Bausatzes konstruierter Roboter
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2006061697A1 (fr) 2004-12-06 2006-06-15 Themis Laboratories Private Limited Compositions de sulfonyluree et procede de preparation de ces dernieres
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
WO2006071184A1 (fr) 2004-12-28 2006-07-06 Astrazeneca Ab Modulateurs de type arylsulfonamide
AU2006239418A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP4981794B2 (ja) 2005-06-03 2012-07-25 アボット・ラボラトリーズ シクロブチルアミン誘導体
JP2007024970A (ja) 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
WO2007034024A2 (fr) 2005-09-21 2007-03-29 Orion Corporation Traitement de symptomes de troubles moteurs
EP1954137A4 (fr) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-ceto-oxazoles en tant que modulateurs d'amide d'acide gras hydrolase
JP4738419B2 (ja) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (fr) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Derives de oxadiazole en tant qu' inhibiteurs de l'enzyme COMT
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
CA2715802A1 (fr) 2008-02-28 2009-09-03 Bial - Portela & C.A., S.A. Composition pharmaceutique destinee a des medicaments peu solubles
AR070907A1 (es) 2008-03-17 2010-05-12 Bial Portela & Ca Sa Formas cristalinas de derivado de nitrocatecol
MX2011001046A (es) 2008-07-29 2011-03-29 Bial Portela & Ca Sa Regimen de administracion para nitrocatecoles.
US8827197B2 (en) 2008-11-04 2014-09-09 Microgreen Polymers Inc Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
ES2915698T3 (es) 2009-04-01 2022-06-24 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
US8294760B2 (en) 2009-04-21 2012-10-23 Samsung Techwin Co., Ltd. Electronic part recognition apparatus and chip mounter having the same
AU2011222856B2 (en) 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
WO2016083863A1 (fr) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Médicaments destinés au ralentissement de la progresssion de la maladie de parkinson

Also Published As

Publication number Publication date
AR058439A1 (es) 2008-02-06
US8907099B2 (en) 2014-12-09
CY2016045I2 (el) 2017-04-05
CA2616377C (fr) 2014-04-01
US9550759B2 (en) 2017-01-24
CN102816157B (zh) 2016-05-18
BRPI0613859B1 (pt) 2020-09-15
JP2013151522A (ja) 2013-08-08
HK1120266A1 (en) 2009-03-27
IL188913A (en) 2013-08-29
US20200102295A1 (en) 2020-04-02
CY1116754T1 (el) 2017-03-15
NO20080981L (no) 2008-04-17
ES2545178T3 (es) 2015-09-09
AU2006272978A1 (en) 2007-02-01
PL1907382T3 (pl) 2016-01-29
PT1907382E (pt) 2015-09-25
US20090054437A1 (en) 2009-02-26
SI1907382T1 (sl) 2015-10-30
AU2006272978B2 (en) 2012-06-07
BRPI0613859A2 (pt) 2011-02-15
CY2016045I1 (el) 2017-04-05
KR20080033243A (ko) 2008-04-16
EP1907382A1 (fr) 2008-04-09
JP2016020366A (ja) 2016-02-04
US20170362213A1 (en) 2017-12-21
LTC1907382I2 (lt) 2017-11-10
KR101370280B1 (ko) 2014-03-06
EP2301934A1 (fr) 2011-03-30
US8168793B2 (en) 2012-05-01
IL188913A0 (en) 2008-04-13
US20120196904A1 (en) 2012-08-02
NL300848I2 (fr) 2017-01-03
CA2616377A1 (fr) 2007-02-01
BRPI0613859B8 (pt) 2021-05-25
CN102816157A (zh) 2012-12-12
NO341886B1 (no) 2018-02-12
JP5517453B2 (ja) 2014-06-11
LTPA2016036I1 (lt) 2017-01-10
HUS000502I2 (hu) 2021-03-29
LU93327I2 (fr) 2017-01-30
HUS1600056I1 (hu) 2017-01-30
US10336740B2 (en) 2019-07-02
HUE025466T2 (en) 2016-02-29
DK1907382T3 (en) 2015-08-31
JP5826201B2 (ja) 2015-12-02
US20150072977A1 (en) 2015-03-12
NO2018013I1 (no) 2018-04-11
JP6280897B2 (ja) 2018-02-14
US20220388999A1 (en) 2022-12-08
WO2007013830A1 (fr) 2007-02-01
NZ565460A (en) 2011-06-30
BRPI0613859A8 (pt) 2018-02-14
JP2009544571A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
US10336740B2 (en) Nitrocatechol derivatives as COMT inhibitors
EP2027091B1 (fr) Nouveaux composés pharmaceutiques
RU2441001C2 (ru) Производные нитрокатехола в качестве ингибиторов сомт
MX2008001094A (en) Nitrocatechol derivatives as comt inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20080619

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIAL-PORTELA & CA, S.A.

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ARAUJO SOARES DA SILVA, PATRICIO MANUEL VIEIRA

Inventor name: DOS SANTOS FERREIRA, HUMBERTO

Inventor name: KISS, LASZLO ERNO

Inventor name: LEARMONTH, DAVID ALEXANDER

Inventor name: LEAL PALMA, PEDRO NUNO

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIAL-PORTELA & CA, S.A.

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 728783

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006045539

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150827

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2545178

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150909

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150812

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E010903

Country of ref document: EE

Effective date: 20150825

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150401783

Country of ref document: GR

Effective date: 20150929

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 19279

Country of ref document: SK

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 728783

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150527

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E025466

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006045539

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160301

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: OPICAPONE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 16C1016

Filing date: 20161129

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCF

Ref document number: 502015000046674

Country of ref document: IT

Free format text: PRODUCT NAME: OPICAPONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ONGENTYS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1066, 20160628

Spc suppl protection certif: 132016000123029

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: C20160052

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPICAPON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 300848

Filing date: 20161212

Expiry date: 20260725

Ref country code: GB

Ref legal event code: CTFF

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/15/1066 20160628

Spc suppl protection certif: SPC/GB16/065

Filing date: 20161124

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 1690058-1

Ref country code: DE

Ref legal event code: R065

Ref document number: 602006045539

Country of ref document: DE

Free format text: PRODUCT NAME: OPICAPON ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: 122016000095

Filing date: 20161202

Expiry date: 20260727

Extension date: 20310628

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 300848

Filing date: 20161212

Expiry date: 20260725

Extension date: 20310627

Effective date: 20170103

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPIKAPONAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: PA2016036

Filing date: 20161213

Expiry date: 20260726

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: 2016/054

Filing date: 20161205

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: CA 2016 00061

Filing date: 20161213

Expiry date: 20260726

Extension date: 20310628

Ref country code: EE

Ref legal event code: AA1Y

Ref document number: E010903

Country of ref document: EE

Free format text: PRODUCT NAME: OPIKAPOON;REG NO/DATE: EU/1/15/1066 28.06.2016

Spc suppl protection certif: C20160042

Filing date: 20161212

REG Reference to a national code

Ref country code: LU

Ref legal event code: CCP

Free format text: PRODUCT NAME: OPICAPONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI

Spc suppl protection certif: 93327

Extension date: 20310629

Ref country code: HU

Ref legal event code: AA1S

Ref document number: E025466

Country of ref document: HU

Free format text: PRODUCT NAME: OPICAPONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: S1600056

Filing date: 20161213

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPIKAPON; REGISTRATION NO/DATE: EU/1/15/1066/001 - EU/1/15/1066/010 20160628

Spc suppl protection certif: 50011-2016

Filing date: 20161208

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCG

Ref document number: 502015000046674

Country of ref document: IT

Free format text: PRODUCT NAME: OPICAPONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ONGENTYS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1066, 20160628

Spc suppl protection certif: 132016000123029

Extension date: 20310626

REG Reference to a national code

Ref country code: DE

Ref legal event code: R067

Ref document number: 602006045539

Country of ref document: DE

Free format text: PRODUCT NAME: OPICAPON ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: 122016000095

Filing date: 20161202

Expiry date: 20260727

Extension date: 20310628

REG Reference to a national code

Ref country code: FR

Ref legal event code: CT

Free format text: PRODUCT NAME: OPICAPONE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 16C1016

Filing date: 20161129

Extension date: 20310628

REG Reference to a national code

Ref country code: DE

Ref legal event code: R069

Ref document number: 602006045539

Country of ref document: DE

Free format text: PRODUCT NAME: OPICAPON ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: 122016000095

Filing date: 20161202

Expiry date: 20260727

Extension date: 20310628

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/15/1066 - ONGENTYS - OPICAPONE

Spc suppl protection certif: 93327

Filing date: 20161130

Expiry date: 20260726

Extension date: 20310629

Effective date: 20170130

Ref country code: LU

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/15/1066 - ONGENTYS - OPICAPONE

Spc suppl protection certif: 93327

Filing date: 20161130

Expiry date: 20260726

Extension date: 20310628

Effective date: 20170130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG1Y

Ref document number: E010903

Country of ref document: EE

Free format text: PRODUCT NAME: OPIKAPOON;REG NO/DATE: EU/1/15/1066 28.06.2016

Spc suppl protection certif: C20160042 00214

Filing date: 20161212

Extension date: 20310628

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: 1690058-1

Expiry date: 20260727

Extension date: 20310627

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPIKAPONAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: PA2016036,C1907382

Filing date: 20161213

Expiry date: 20260726

Extension date: 20310628

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1066 20160624

Spc suppl protection certif: 2016/054

Extension date: 20310627

Effective date: 20171220

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPIKAPON VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1066/001 - EU/1/15/1066/010 20160628

Spc suppl protection certif: 271 50011-2016

Filing date: 20161208

Extension date: 20310628

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFG

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628

Spc suppl protection certif: CR 2016 00061

Filing date: 20161213

Expiry date: 20260726

Extension date: 20310628

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCF

Ref document number: 728783

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: OPICAPON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1066 (MITTEILUNG) 20180628

Spc suppl protection certif: 57/2016

Filing date: 20161201

Effective date: 20180715

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCG

Ref document number: 728783

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: OPICAPON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1066 (MITTEILUNG) 20160628

Spc suppl protection certif: 57/2016

Filing date: 20161201

Expiry date: 20260726

Extension date: 20310628

Effective date: 20180815

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: OPICAPON; REGISTRATION NO/DATE: SWISSMEDIC 66547 26.04.2018

Filing date: 20181017

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPON; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66547 26.04.2018

Spc suppl protection certif: C01907382/01

Filing date: 20181017

Extension date: 20310725

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/15/1066 20160628

Spc suppl protection certif: SPC/GB16/065

Filing date: 20161124

Effective date: 20201120

REG Reference to a national code

Ref country code: HU

Ref legal event code: FG4S

Ref document number: E025466

Country of ref document: HU

Spc suppl protection certif: S1600056

Filing date: 20161213

REG Reference to a national code

Ref country code: RO

Ref legal event code: SPCG

Free format text: PRODUCT NAME: OPICAPONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1066; DATE OF NATIONAL AUTHORISATION: 20160624; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1066; DATE OF FIRST AUTHORISATION IN EEA: 20160624

Spc suppl protection certif: C 2016 044

Extension date: 20310628

Effective date: 20211230

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCX

Free format text: CORRECTION OF GRANT INFORMATION ON SUPPLEMENTARY PROTECTION CERTIFICATE APPLICATIONSAPPLICANT: BIAL-PORTELA & CA, S.A.A AVENIDA DA SIDERURGIA, NACIONAL, 4745-457 S.MAMEDE DO CORONADO, PORTUGALPRODUCT: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREO FPRODUCT TYPE: MEDICINAL AUTHORISED: UK EU/1/15/1066/001/010 28 JUNE 2016 AUTHORISED EXTENSION: PATENT NO: EP1907382 TITLE: NITROCATECHOL DERIVATIVES AS COMT INHIBITORS SPC NO: SPC/GB16/065DATE GRANTED: 20 NOVEMBER 2020 MAXIMUM PERIOD EXPIRES ON: 27 JUNE 2031*CORRECTION OF GRANT DETAILS IN JOURNAL NUMBER 6865 DATED 16 DECEMBER 2020 TO INCLUDE MAXIMUM EXPIRY DETAILS AND UPDATED AUTHORISATION DETAILS.

Spc suppl protection certif: SPC/GB16/065

Extension date: 20310627

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCG

Spc suppl protection certif: 706

Extension date: 20310628

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230720

Year of fee payment: 18

Ref country code: RO

Payment date: 20230726

Year of fee payment: 18

Ref country code: IT

Payment date: 20230719

Year of fee payment: 18

Ref country code: ES

Payment date: 20230926

Year of fee payment: 18

Ref country code: EE

Payment date: 20230728

Year of fee payment: 18

Ref country code: CZ

Payment date: 20230720

Year of fee payment: 18

Ref country code: CY

Payment date: 20230724

Year of fee payment: 18

Ref country code: CH

Payment date: 20230802

Year of fee payment: 18

Ref country code: AT

Payment date: 20230720

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230719

Year of fee payment: 18

Ref country code: SI

Payment date: 20230720

Year of fee payment: 18

Ref country code: SE

Payment date: 20230719

Year of fee payment: 18

Ref country code: PL

Payment date: 20230719

Year of fee payment: 18

Ref country code: HU

Payment date: 20230721

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20230719

Year of fee payment: 18

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCN

Spc suppl protection certif: C01907382/01

Representative=s name: E. BLUM AND CO. AG, CH

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240719

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240719

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240722

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240722

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240719

Year of fee payment: 19

Ref country code: MC

Payment date: 20240723

Year of fee payment: 19

Ref country code: FI

Payment date: 20240722

Year of fee payment: 19

Ref country code: IE

Payment date: 20240722

Year of fee payment: 19

Ref country code: LT

Payment date: 20240724

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240723

Year of fee payment: 19

Ref country code: DK

Payment date: 20240726

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20240718

Year of fee payment: 19

Ref country code: GB

Payment date: 20240712

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240719

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240729

Year of fee payment: 19